SCHEMBL164391

SCHEMBL164391

COC(=O)c1csnc1[O]

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.39
TSHR P16473 2/20 0.38
LMNA P02545 1/20 0.38
ALDH1A1 P00352 3/20 0.37
HSD17B10 Q99714 2/20 0.37
CFTR P13569 1/20 0.37
KDM4E B2RXH2 5/20 0.37
GAA P10253 4/20 0.37
GLA P06280 3/20 0.37
NPSR1 Q6W5P4 1/20 0.37
CA12 O43570 2/20 0.36
CA1 P00915 2/20 0.36
CA2 P00918 2/20 0.36
CA7 P43166 2/20 0.36
CA9 Q16790 2/20 0.36
CA14 Q9ULX7 2/20 0.36
ATM Q13315 2/20 0.36
POLB P06746 1/20 0.36
PDK2 Q15119 1/20 0.36
PDK4 Q16654 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14649415 0.80 MAPT (0.42) MAPTTSHRLMNAALDH1A1HSD17B10
SCHEMBL162511 0.79 TSHR (0.48) MAPTTSHRLMNAALDH1A1HSD17B10
SCHEMBL162643 0.79 GRM6 (0.33) MAPTALDH1A1HSD17B10NPSR1CA12
SCHEMBL166342 0.79 CA12 (0.41) MAPTTSHRLMNAALDH1A1HSD17B10
SCHEMBL162639 0.77 ALDH1A1 (0.51) TSHRLMNAALDH1A1HSD17B10KDM4E
SCHEMBL163608 0.76 SLC6A2 (0.37) LMNAALDH1A1KDM4EGAAPOLB
SCHEMBL13485162 0.76 GCGR (0.35) MAPTTSHRLMNAALDH1A1HSD17B10
SCHEMBL161119 0.76 ALOX5 (0.39) TSHRALDH1A1KDM4EGAASMN1; SMN2
SCHEMBL163284 0.75 ALDH1A1 (0.53) MAPTTSHRLMNAALDH1A1HSD17B10
SCHEMBL165450 0.74 TSHR (0.54) TSHRLMNAALDH1A1HSD17B10KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9856210-B2 Pharmaceutical composition for prevention and treatment of amyotrophic lateral sclerosis KYOTO UNIVERSITY (JP) 2018-01-02 US disclosed
EP-2611437-B1 PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS UNIV KYOTO (JP) 2017-03-29 EP disclosed
US-20130225642-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS KYOTO UNIVERSITY (JP) 2013-08-29 US disclosed
EP-2611437-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS Kyoto University (JP) 2013-07-10 EP disclosed
WO-2012029994-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS KYOTO UNIVERSITY (JP) 2012-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130225642-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS SMN1; SMN2, SOD1, SOD3 MAPT 261/4885TSHR 4862/4885LMNA 462/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.